Skip to main content

Advertisement

Log in

The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Objective

The aim of this study was to investigate the efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.

Methods

Designed as a retrospective study, a total of 105 metastatic osteosarcoma patients who progressed after standard therapy were included in this study. The metastatic osteosarcoma patients received 500–750 mg Apatinib mesylate according to body surface area until disease progression or unacceptable toxicity with 28 days one cycle. Overall response was evaluated after two cycles Apatinib treatment, then progression-free survival (PFS) and overall survival (OS) were evaluated, and safety data were recorded. Additionally. peripheral blood and peripheral blood mononuclear cell (PBMC) specimens in the osteosarcoma patients were collected for the genotyping of VEGFR2 genetic variation and mRNA expression, respectively. Analysis on the association between genotype and baseline characteristics and VEGFR2 gene mRNA expression was analyzed. The univariate analysis of genotypes and prognosis was carried out by Kaplan–Meier survival analysis, and multivariate analysis was adjusted by Cox regression analysis.

Results

The objective response rate (ORR) of the 105 metastatic osteosarcoma patients was 37.14%, disease control rate (DCR) was 77.14%, median PFS was 4.1 months, and median OS was 9.0 months. Regarding the VEGFR2 gene polymorphisms analysis, only − 906 T > C was of clinical significance. The prevalence of − 906 T > C in VEGFR2 among the study population was as follows: TT genotype 62 cases (59.05%), TC genotype 36 cases (34.29%) and CC genotype 7 cases (6.66%), minor allele frequency of − 906 T > C was 0.24. Compared with patients with TC/CC genotype, patients with TT genotype showed longer median PFS (5.0 versus 3.1 months, P = 0.011) and median OS (9.8 versus 7.6 months, P = 0.032). There was no correlation between the polymorphism and adverse reactions. Additionally, the mRNA expression in 69 randomly selected sample indicated that the mRNA expression of VEGFR2 of the patients with CC/TC genotypes were significantly higher than those of the TT genotype patients (P < 0.001).

Conclusion

Apatinib was safe and effective in the treatment of metastatic osteosarcoma patients who progressed after standard therapy. The clinical outcomes of Apatinib may be influenced by the polymorphism − 906 T > C of VEGFR2 through mediating the mRNA expression of VEGFR2.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132

    Article  PubMed  Google Scholar 

  2. Tirtei E, Asaftei SD, Manicone R et al (2018) Survival after second and subsequent recurrences in osteosarcoma: a retrospective multicenter analysis. Tumori 104:202–206

    Article  PubMed  Google Scholar 

  3. Zhang T, Zhang S, Yang F et al (2018) Efficacy comparison of six chemotherapeutic combinations for osteosarcoma and ewing's sarcoma treatment: a network meta-analysis. J Cell Biochem 119:250–259

    Article  CAS  PubMed  Google Scholar 

  4. Davis LE, Bolejack V, Ryan CW et al (2019) Randomized double-blind Phase II study of regorafenib in patients with metastatic osteosarcoma. J Clin Oncol 37:1424–1431

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Lagmay JP, Krailo MD, Dang H et al (2016) Outcome of patients with recurrent osteosarcoma enrolled in seven phase II trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: learning from the past to move forward. J Clin Oncol 34:3031–3038

    Article  PubMed  PubMed Central  Google Scholar 

  6. Qin S, Li A, Yi M et al (2019) Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol 12:27

    Article  PubMed  PubMed Central  Google Scholar 

  7. Grignani G, Palmerini E, Dileo P et al (2012) A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 23:508–516

    Article  CAS  PubMed  Google Scholar 

  8. Coventon J (2017) A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma. J Bone Oncol 8:4–7

    Article  PubMed  PubMed Central  Google Scholar 

  9. Duffaud F, Mir O, Boudou-Rouquette P et al (2019) Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 20:120–133

    Article  CAS  PubMed  Google Scholar 

  10. Fioramonti M, Fausti V, Pantano F et al (2018) Cabozantinib affects osteosarcoma growth through a direct effect on tumor cells and modifications in bone microenvironment. Sci Rep 8:4177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Li J, Qin S, Xu J et al (2016) Randomized, double-blind, placebo-controlled Phase III trial of Apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol 34:1448–1454

    Article  CAS  PubMed  Google Scholar 

  12. Liu K, Ren T, Huang Y et al (2017) Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death Dis 8:e3015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Zheng B, Ren T, Huang Y et al (2018) Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3. Biochem Biophys Res Commun 495:1695–1701

    Article  CAS  PubMed  Google Scholar 

  14. Xie L, Xu J, Sun X et al (2019) Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label Phase II clinical trial. Oncologist 24:e542–e550

    CAS  PubMed  Google Scholar 

  15. Liao Z, Li F, Zhang C et al (2019) Phase II trial of VEGFR2 inhibitor Apatinib for metastatic sarcoma: focus on efficacy and safety. Exp Mol Med 51:24

    Article  PubMed Central  CAS  Google Scholar 

  16. Zhao D, Hou H, Zhang X (2018) Progress in the treatment of solid tumors with apatinib: a systematic review. Onco Targets Ther 11:4137–4147

    Article  PubMed  PubMed Central  Google Scholar 

  17. Tang L, Yu W, Wang Y et al (2019) Anlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma. Clin Transl Oncol 21:1624–1633

    Article  CAS  PubMed  Google Scholar 

  18. Liu X, Qin S, Wang Z et al (2018) Correction to: early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol 11:5

    Article  PubMed  PubMed Central  Google Scholar 

  19. Liu S, Wu M, Zhang B et al (2019) Analysis of genetic polymorphisms for age-related macular degeneration (AMD) in Chinese Tujia ethnic minority group. BMC Med Genet 20:25

    Article  PubMed  PubMed Central  Google Scholar 

  20. Babyshkina N, Zavyalova M, Tarabanovskaya N et al (2018) Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapy. Mol Cell Biochem 444:197–206

    Article  CAS  PubMed  Google Scholar 

  21. Escudier B, Rini BI, Motzer RJ et al (2015) Genotype correlations with blood pressure and efficacy from a randomized Phase III trial of second-line axitinib versus sorafenib in metastatic renal cell carcinoma. Clin Genitourin Cancer 13:328–337.e323

    Article  PubMed  Google Scholar 

  22. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  CAS  PubMed  Google Scholar 

  23. Miller TP, Fisher BT, Getz KD et al (2019) Unintended consequences of evolution of the common terminology criteria for adverse events. Pediatr Blood Cancer 66:e27747

    Article  PubMed  PubMed Central  Google Scholar 

  24. Tian Z, Gu Z, Wang X et al (2019) Efficacy and safety of Apatinib in treatment of osteosarcoma after failed standard multimodal therapy: an observational study. Medicine (Baltimore) 98:e15650

    Article  CAS  Google Scholar 

  25. Chen X, Qiu T, Zhu Y et al (2019) A single-arm, Phase II study of Apatinib in refractory metastatic colorectal cancer. Oncologist 24:883–e407

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Chen LT, Oh DY, Ryu MH et al (2017) Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: a systematic review. Cancer Res Treat 49:851–868

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Liu X, Qin S, Wang Z et al (2017) Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol 10:153

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Fang SC, Huang W, Zhang YM et al (2019) Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with Apatinib. Onco Targets Ther 12:985–992

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Wei JH, Feng ZH, Cao Y et al (2019) Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study. Lancet Oncol 20:591–600

    Article  CAS  PubMed  Google Scholar 

  30. Agemi Y, Shimokawa T, Sasaki J et al (2019) Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: a single-institution study. PLoS ONE 14:e0210499

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Zhu B, Li J, Xie Q et al (2018) Efficacy and safety of Apatinib monotherapy in advanced bone and soft tissue sarcoma: an observational study. Cancer Biol Ther 19:198–204

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Scartozzi M, Faloppi L, Baroni GS et al (2014) VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer 135:1247–1256

    Article  CAS  PubMed  Google Scholar 

  33. Sullivan I, Riera P, Andres M et al (2019) Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients. Angiogenesis 22:433–440

    Article  CAS  PubMed  Google Scholar 

  34. George DJ, Martini JF, Staehler M et al (2019) Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: exploratory pharmacogenomic analysis. Clin Cancer Res 25:1165–1173

    Article  PubMed  CAS  Google Scholar 

  35. Zhu Y, Feng B, Mei L et al (2019) Clinical efficacy of TACE combined with Apatinib in the treatment of advanced hepatocellular carcinoma. J BUON 24:608–614

    PubMed  Google Scholar 

  36. Li J, Jia Y, Gao Y et al (2019) Clinical efficacy and survival analysis of Apatinib combined with docetaxel in advanced esophageal cancer. Onco Targets Ther 12:2577–2583

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Xie L, Xu J, Sun X et al (2018) Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label phase II clinical trial. Oncologist 24:e542–e550

    PubMed  PubMed Central  Google Scholar 

  38. Cho HD, Moon KD, Park KH et al (2018) Effects of auriculasin on vascular endothelial growth factor (VEGF)-induced angiogenesis via regulation of VEGF receptor 2 signaling pathways in vitro and in vivo. Food Chem Toxicol 121:612–621

    Article  CAS  PubMed  Google Scholar 

  39. Lu Y, Xu Q, Zuo Y et al (2017) Isoprenaline/beta2-AR activates Plexin-A1/VEGFR2 signals via VEGF secretion in gastric cancer cells to promote tumor angiogenesis. BMC Cancer 17:875

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Jinesh GG, Manyam GC, Mmeje CO et al (2017) Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis. Sci Rep 7:9602

    Article  PubMed  PubMed Central  Google Scholar 

  41. Ding M, Liu L, Hu C et al (2014) Expression of VEGFR2 and NRP-1 in non-small cell lung cancer and their clinical significance. Chin J Cancer Res 26:669–677

    PubMed  PubMed Central  Google Scholar 

  42. Dang YZ, Zhang Y, Li JP et al (2017) High VEGFR1/2 expression levels are predictors of poor survival in patients with cervical cancer. Medicine (Baltimore) 96:e5772

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Jia-Yong Liu or Xin Sun.

Ethics declarations

Conflict of interest

All authors declare that there is no conflict of interest.

Ethical approval

This study was approved by the Ethics Committee of Peking University Cancer Hospital.

Informed consent

The written informed consent was obtained from all the patients.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, JY., Zhu, BR., Wang, YD. et al. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis. Int J Clin Oncol 25, 1195–1205 (2020). https://doi.org/10.1007/s10147-020-01644-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-020-01644-7

Keywords

Navigation